Compare QH & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QH | FEMY |
|---|---|---|
| Founded | 2012 | 2004 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.8M | 12.0M |
| IPO Year | 2019 | 2021 |
| Metric | QH | FEMY |
|---|---|---|
| Price | $4.62 | $2.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | 26.1K | ★ 143.8K |
| Earning Date | 04-02-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 44.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,293,313.00 |
| Revenue This Year | N/A | $105.16 |
| Revenue Next Year | N/A | $200.23 |
| P/E Ratio | $2.86 | ★ N/A |
| Revenue Growth | N/A | ★ 40.77 |
| 52 Week Low | $0.06 | $0.29 |
| 52 Week High | $12.81 | $6.29 |
| Indicator | QH | FEMY |
|---|---|---|
| Relative Strength Index (RSI) | 45.63 | 34.61 |
| Support Level | $3.90 | $0.41 |
| Resistance Level | $5.40 | $3.21 |
| Average True Range (ATR) | 0.49 | 0.28 |
| MACD | 0.02 | -0.07 |
| Stochastic Oscillator | 40.67 | 15.80 |
Quhuo Ltd is a gig economy platform focusing on local life services in China. It provide tech-enabled, end-to-end operational solutions to consumer service businesses, including on-demand delivery solutions, mobility service solutions, housekeeping and accommodation solutions, and other services. Its three operating segments, include (i) on-demand delivery solutions, (ii) mobility service solutions, and (iii) housekeeping and accommodation solutions and other services. It generates maximum of its revenue from the on-demand delivery solutions segment.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.